Released on = March 30, 2006, 12:31 pm

Press Release Author = Biophan

Industry = Biotech

Press Release Summary = Biophan-Europe to Enter into Negotiations for a Joint R&D
Agreement with Siemens Medical Solutions MRI Division

Press Release Body = Biophan Technologies, Inc. (OTCBB: BIPH - News; FWB: BTN), a
developer of next-generation medical technology, announced today a declaration of
intent to enter into negotiations for a strategic research collaboration between
Siemens\' Medical Solutions MRI Division in Europe and Biophan Europe GmbH, designed
to provide new solutions in the growing field of interventional MRI medicine and
MRI-assisted minimally invasive surgeries.

The anticipated collaboration follows discussions between senior officers of the two
companies to further develop and commercialize potentially complementary Magnetic
Resonance Imaging (MRI) technologies. Biophan Europe is emerging as a major force of
innovative solutions to enable effective MRI visualization of implanted medical
devices, including heart valves, coronary and peripheral stents and vena cava
filters.

Siemens\' MRI Division, in turn, has developed a new MRI scanning technology with
aperture configurations that could be highly complementary to Biophan\'s research and
development program in this area, according to Dr. Michael Friebe, CEO of
Biophan-Europe.

\"Siemens new 1.5 Tesla Open Bore MR MAGNETOM Espree with Tim technology, with its
wide aperture, will be ideally suited for MRI-related interventional procedures,
combined with our own expertise under Chief Technology Officer Dr. Andreas Melzer in
positioning and interventional support hardware form a solid foundation for
partnership and further joint development of medically needed MRI scanning
solutions,\" Dr. Friebe said.

Currently, many implantable and surgical devices comprised of metallic elements are
contraindicated for use with MRI due to their potential undesirable interactions
with the powerful electromagnetic fields generated by MRI systems. To extend MRI to
patients with implantable devices, who currently are denied access to MRI
visualization, Biophan has developed a variety of proprietary technologies to enable
MR imaging to visualize the interiors of stents and other implants, and to enable
the MRI-guided implantation of devices.

\"This exciting opportunity for Biophan to collaborate with Siemens marks another
milestone in Biophan\'s growing technological and marketplace leadership,\" said
Michael Weiner, CEO of Biophan Technologies. \"We\'re excited about this opportunity
to work with a company of Siemens\' well-recognized leadership in medical imaging.\"

About Siemens

Siemens Medical Solutions of Siemens AG (NYSE: SI - News), with headquarters in
Malvern, Pennsylvania and Erlangen, Germany, is one of the largest suppliers to the
healthcare industry in the world. The company is known for bringing together
innovative medical technologies, healthcare information systems, management
consulting, and support services, to help customers achieve tangible, sustainable,
clinical and financial outcomes. More information can be obtained by visiting
http://www.usa.siemens.com/medical.

About Biophan

Biophan develops and markets cutting-edge technologies for the medical device
industry that provide competitive advantages. The Company\'s founding goal was to
make all biomedical devices capable of safely and successfully working with magnetic
resonance imaging (MRI), problems which the Company has solved and begun to license
to leading device manufacturers. The Company\'s mission has expanded to provide other
technologies which will improve the delivery of healthcare. Biophan\'s technologies
enable medical systems such as pacemakers, interventional surgical devices such as
catheters and guidewires, and implants such as stents to be safely and/or
effectively imaged under MRI. The Company is helping to commercialize the
MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant
potential to improve the treatment of many forms of acute and chronic heart disease.
Other applications in development include drug delivery and power systems which
derive energy from body heat. Committed to growth through innovation and
developmental leadership, Biophan and its licensors now hold a total of 156 U.S.
patents, licenses, or applications, plus international applications. This total
includes 50 issued U.S. patents, 8 recently-allowed applications that will issue as
patents in the near future, and 98 pending applications at various stages of
examination at the U.S. Patent and Trademark Office. The patents cover areas
including nanotechnology (nanomagnetic particle coatings), medical device designs,
radio frequency filters, polymer composites, thermoelectric materials, and
photonics. Biophan has joint development and licensing agreements with Boston
Scientific Corporation and NASA\'s Ames Center for Nanotechnology. Biophan is traded
on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock
Exchange under the symbol BTN.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking
statements within the meaning of applicable securities laws. These statements
reflect what Biophan anticipates, expects, or believes may happen in the future.
Biophan\'s actual results could differ materially from the outcome or circumstance
expressed or implied by such forward-looking statements as a result of a variety of
factors including, but not limited to: Biophan\'s ability to develop its
technologies; the approval of Biophan\'s patent applications; the successful
implementation of Biophan\'s research and development programs; the ability of
Biophan to demonstrate the effectiveness of its technology; the acceptance by the
market of Biophan\'s technology and products incorporating such technology, the
ability of Biophan to effectively negotiate and enter into contracts with medical
device manufacturers for the licensing of Biophan\'s technology; competition; the
ability of Biophan to raise capital to fund its operating and research and
development activities until it generates revenues sufficient to do so; and the
timing of projects and trends in future operating performance, as well as other
factors expressed from time to time in Biophan\'s periodic filings with the
Securities and Exchange Commission (the \"SEC\"). As a result, this press release
should be read in conjunction with Biophan\'s periodic filings with the SEC, which
are incorporated herein by reference. The forward-looking statements contained
herein are made only as of the date of this press release, and Biophan undertakes no
obligation to publicly update such forward-looking statements to reflect subsequent
events or circumstances.

Web Site = http://www.zangani.com

Contact Details = Zangani Investor Community
Kevin Nally
9 Main Street
Flemington, NJ 08822
908-788-9660
office@zangani.com